The BETADINE^®Mosaic Summit 2025, which brought together more than 150 doctors, pharmacists, and experts from leading healthcare institutions across Egypt and Saudi Arabia, signaled the entry and strong commitment of iNova Pharmaceuticals to innovation investment and growth in the Egyptian and Middle Eastern markets.

Importantly the coordination and delivery of this major scientific event come at the same time the region is experiencing a significant increase in demand for disinfection and primary-care products both in hospitals and in the community, making the Egyptian market a strategic destination for the company’s continued expansion in the coming period.

BETADINE^® Egypt with a new vision after its acquisition by iNova pharmaceuticals

The acquisition of the iconic Betadine portfolio of products marks a new chapter in the history of the trusted brand, which has been trusted by healthcare professionals and used worldwide for more than 60 years in disinfection and infection control.

Egypt represents one of the key strategic for iNova pharmaceuticals in the Middle East and Africa region. According to 2025 reports, the medical supplies market in the region is witnessing a significant growth rate at 6.42%, along with rising demand for disinfection and infection-control products in hospitals and medical centers.

Global growth in the infection-prevention sector supports Inova’s new presence

According to the Infection Prevention Market Report 2025, the global infection-prevention market reached $45.01 billion in 2025, with a compound annual growth rate of 3.7%.

The share of infection-prevention supplies, including Betadine products, reached 40.4% of the total market in 2025, according to a report by Future Market Insights.

In the Middle East and North Africa, the wound-wash market reached $2.12 billion in 2024, with expectations of further growth in 2025, highlighting the critical role of BETADINE® in shaping the future of the category

A Scientific Summit Bringing Together Leading Physicians from Egypt and Saudi Arabia

The Scientific Summit hosted a distinguished group of specialists from major hospitals, including:
Ahl Masr, Cleopatra, Dar Al Fouad, Nasser Institute, Ain Shams, Qasr Al Ainy, Saudi German Hospital, Andalusia Group, and Dr. Sulaiman Al Habib Hospital.

Day One: Surgery and Infection Control

The first day featured scientific discussions on:
• Surgical Site Infections (SSI)
• Antibiotic resistance
• The role of BETADINE^®achieving clean and rapid wound healing

With participation from:
Dr. Gehan Fahmy – Dr. Sherine El-Masry – Dr. Hossam El-Kafrawy – Dr. Mohamed Azazi

Dr. Magid Mahmoud also delivered an extensive review on the use of Betadine® across various medical specialties.

Day Two: Respiratory System & Obstetrics and Gynecology

The second day included two main sessions:
• Upper Respiratory Tract Infections (URTI) and the role of Betadine as an antiviral and antibacterial agent, presented by Dr. Ehab Kamal and Dr. Anas Askoura
• Recurrent and resistant vaginal infections, discussed by leading OB/GYN specialists:
Dr. Ayman Aboul Nour – Dr. Hassan Ghaffar – Dr. Ehab Sirag – Dr. Amr Ghaffar

The event organization received wide praise from participants, thanks to the efforts of the iNova team:
Ban Mwala – Moataz El-Sayed – Marian Ramzy – led by Nora Khayata.

Inova’s Vision: Supporting Medical Education and Building Long-Term Partnerships

The company’s regional management—represented by:
Dr. Amr El-Gammal (GM – MENA)
Dr. Ahmed Abu El-Nasr (National Sales Manager – Egypt)
Dr. Mostafa Kamel (National Sales Manager – KSA & GCC)

confirmed that entering the Egyptian market marks the beginning of a long-term strategy focused on:
• Expanding continuous medical education (CME) programs
• Enhancing awareness of infection-prevention practices
• Planned launches of new product innovations in Egypt
• Building strong collaborations with healthcare institutions

The company emphasized that the summit is not an isolated event but the start of a series of scientific activities aimed at establishing Betadine as a key component in the region’s infection-prevention ecosystem.

From a Global Legacy to a New Regional Presence

The acquisition of Betadine by iNova marked the beginning of a new phase of innovation, , scientific advancement, and expansion into fast-growing markets for the global consumer healthcare company.

With the convening of the Betadine Mosaic Summit 2025 in Cairo, iNova solidifies its official entry into Egypt and it’s intention to invest in close collaboration with doctors and pharmacists to provide advanced infection-prevention solutions and enhance the quality of healthcare.

About iNova Pharmaceuticals

iNova Pharmaceuticals is a privately owned business specializing in consumer health products and prescription medicines.

iNova pharmaceuticals is a leader in consumer healthcare delivering innovative, patient-centric solutions that improve the lives of people around the world. Our portfolio includes well-known, trusted brands including BETADINE^â, Difflam^â, DURO-TUSS^â, DermaVeen^â and Demazin^â among many others.

Headquartered in Singapore, today our products are distributed in over 75 markets across Asia, Australia, New Zealand, Middle East & Africa and Europe.

The company focuses on developing innovative health solutions in the fields of:
• Infection prevention
• Wound care
• Throat, cough, cold and flu management
• Skincare
• Women’s health
• Prescription medications